Abstract
No drug-drug interaction study has been conducted to date for the combination of ombitasvir, paritaprevir/ritonavir, dasabuvir (3D), and mycophenolic acid (MPA). We here report the case of a hepatitis C virus-infected patient treated with 3D and MPA for vasculitis. In light of the threat of drug-drug interaction, the concentration of MPA was measured before, during, and 15 days after the end of the 3D treatment. Similar values were found at all 3 time points, thus indicating that there is probably no need to adapt MPA dosage to 3D.
MeSH terms
-
2-Naphthylamine
-
Aged
-
Anilides / administration & dosage
-
Anilides / blood*
-
Antibiotics, Antineoplastic / administration & dosage
-
Antibiotics, Antineoplastic / blood
-
Antiviral Agents / administration & dosage
-
Antiviral Agents / blood
-
Carbamates / administration & dosage
-
Carbamates / blood*
-
Cyclopropanes
-
Cytochrome P-450 CYP3A Inhibitors / administration & dosage
-
Cytochrome P-450 CYP3A Inhibitors / blood
-
Disease Management
-
Drug Interactions / physiology
-
Drug Monitoring / methods
-
Drug Therapy, Combination
-
Hepatitis C / blood*
-
Hepatitis C / diagnosis
-
Hepatitis C / drug therapy
-
Humans
-
Lactams, Macrocyclic
-
Macrocyclic Compounds / administration & dosage
-
Macrocyclic Compounds / blood*
-
Male
-
Mycophenolic Acid / administration & dosage
-
Mycophenolic Acid / blood*
-
Proline / analogs & derivatives
-
Ritonavir / administration & dosage
-
Ritonavir / blood*
-
Sulfonamides / administration & dosage
-
Sulfonamides / blood*
-
Uracil / administration & dosage
-
Uracil / analogs & derivatives*
-
Uracil / blood
-
Valine
Substances
-
Anilides
-
Antibiotics, Antineoplastic
-
Antiviral Agents
-
Carbamates
-
Cyclopropanes
-
Cytochrome P-450 CYP3A Inhibitors
-
Lactams, Macrocyclic
-
Macrocyclic Compounds
-
Sulfonamides
-
ombitasvir
-
Uracil
-
Proline
-
2-Naphthylamine
-
dasabuvir
-
Valine
-
Mycophenolic Acid
-
Ritonavir
-
paritaprevir